Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Global OLE of Patisiran in hATTR Amyloidosis
NCT02510261Phase 3Completed
- Sponsor
- Alnylam Pharmaceuticals
- Start
- Jul 2015
- Primary completion
- Nov 2022
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 21
01
Overview
A Phase 3 trial of patisiran in hereditary transthyretin amyloidosis (hATTR), sponsored by Alnylam Pharmaceuticals. Started Jul 2015; status: completed.
02
Drugs
patisiran
03
Conditions
hereditary transthyretin amyloidosis (hATTR)
Beyond the preview
Go deeper on NCT02510261.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02510261.